Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Floxuridine is an antimetabolite chemotherapy drug primarily used for the palliative management of liver metastases from gastrointestinal tract cancers, especially colorectal cancer. It is a pyrimidine analog (specifically a deoxyuridine derivative) that acts by inhibiting DNA synthesis in rapidly dividing cells. After administration, floxuridine is rapidly converted to 5-fluorouracil (5-FU), which inhibits thymidylate synthase and disrupts the incorporation of thymidine nucleotides into DNA, thereby blocking cell division during the S-phase of the cell cycle. Floxuridine is typically administered via continuous intra-arterial infusion directly to the hepatic artery supplying blood to liver tumors.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on floxuridine.